Cullinan Therapeutics announced four major updates for Q4 2026 across its T cell engager pipeline, including multi-dose SLE data for CLN-978 in December and Phase 1 updates for velinotamig in November and CLN-049 in December.
Cullinan Therapeutics announced four major updates for Q4 2026 across its T cell engager pipeline, including multi-dose SLE data for CLN-978 in December and Phase 1 updates for velinotamig in November and CLN-049 in December.